- Approval Id
- cf11dbb002bca7b3
- Drug Approval Emc Name
- Trimipramine 50mg Capsules
- Drug Name
- Trimipramine 50mg Capsules
- Company Name
- Glenmark Pharmaceuticals Europe Ltd
- Company Address
- Building 2, Croxley Park, Watford, WD18 8YA
- Company Website
- //www.glenmarkpharma.com
- Company Telephone
- +44 (0)1923 202 950
- Company Medical Info Direct Line
- 0800 458 0383
- Company Stock Availability
- +44 (0)1923 202 950
- Atc Code
- N06AA06
- Legal Category
- Prescription only medicine
- Authorisation Holder
- Glenmark Pharmaceuticals Europe Limited
Laxmi House, 2B Draycott Avenue, Kenton, Middlesex
HA3 0BU
United Kingdom
- Authorisation Number
- PL 25258/0330
- Authorisation Date
- 21/07/2021
- Instruction Authorisation Holder
- Glenmark Pharmaceuticals Europe Limited
Laxmi House, 2B Draycott Avenue, Kenton, Middlesex
HA3 0BU
United Kingdom
- Instruction Authorisation Number
- PL 25258/0330
- Instruction Authorisation Date
- 21/07/2021
- Instruction Composition
- Each capsule contains 69.75mg of Trimipramine Maleate, equivalent to 50mg Trimipramine.
Excipients with known effect:
Each capsule contains 1.40 mg of sodium.
For the full list of excipients, see Section 6.1.
- Instruction Dosage Form
- Capsule
Hard gelatin capsules approximately 19.20 x 6.93 mm in size with white opaque body imprinted with “301” in black ink and green cap imprinted with Glenmark logo “G” in black ink, filled with white to pale yellow powder.
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
Trimipramine has a potent antidepressant action similar to that of other tricyclic antidepressants. It also possesses pronounced sedative action. It is, therefore, indicated in the treatment of depressive illness, especially where sleep disturbance, anxiety or agitation are presenting symptoms. Sleep disturbance is controlled within 24 hours and true antidepressant action follows within 7 to 10 days.4.2 Posology and method of administration
\*\*Posology\*\*
\*Adults\*
For depression 50-75 mg/day initially increasing to 150-300 mg/day in divided doses or one dose at night. The maintenance dose is 75-150 mg/day.
\*Elderly\*
10-25 mg three times a day initially. The initial dose should be increased with caution under close supervision. Half the normal maintenance dose may be sufficient to produce a satisfactory clinical response.
\*\*\*Paediatric population\*\*\*
Not recommended.
\*\*Method of administration\*\*
Oral.4.3 Contraindications
• Recent myocardial infarction
• Any degree of heart block or other cardiac arrhythmias
• Mania
• Severe liver disease
• During breast feeding
• Hypersensitivity to trimipramine maleate or to any of the excipients4.4 Special warnings and precautions for use
\*\*\*\*Suicide/suicidal thoughts or clinical worsening\*\*\*\*
Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.
Other psychiatric conditions for which Trimipramine is prescribed can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders.
Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.
Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.
\*\*Hyperglycaemia/Diabetes:\*\*
Epidemiologic studies have identified an increased risk of diabetes mellitus in depressed patients receiving tricyclic antidepressants. Therefore, patients with an established diagnosis of diabetes mellitus or with risk factors for diabetes who are started on trimipramine, should get appropriate glycaemic monitoring (see section 4.8).
\*\*Serotonin Syndrome:\*\*
Concomitant administration of Trimipramine and buprenorphine/opioids may result in serotonin syndrome, a potentially life-threatening condition (see section 4.5).
If concomitant treatment with other serotonergic agents is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
Symptoms of serotonin syndrome may include mental-status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms.
If serotonin syndrome is suspected, a dose reduction or discontinuation of therapy should be considered depending on the severity of the symptoms.
\*\*QT interval prolongation:\*\*
Like other tricyclic antidepressants, trimipramine may dose-dependently prolong QT interval (see section 4.8).
Caution should be taken in patients with known risk factors for prolongation of QT interval such as:
• congenital long QT syndrome, bradycardia
• concomitant use of drugs that are known to prolong the QT interval, induce bradycardia or hypokalemia (see section 4.5)
• uncorrected electrolyte imbalance (e.g. hypokalemia, hypomagnesemia).
The elderly are particularly liable to experience adverse reactions, especially agitation, confusion and postural hypotension.
Avoid if possible in patients with narrow angle glaucoma, symptoms suggestive of prostatic hypertrophy and a history of epilepsy.
Patients posing a high suicidal risk require close initial supervision. Tricyclic antidepressants potentiate the central nervous depressant action of alcohol.
Anaesthetics given during tri/tetracyclic antidepressant therapy may increase the risk of arrhythmias and hypotension. If surgery is necessary, the anaesthetist should be informed that a patient is being so treated.
It may be advisable to monitor liver function in patients on long term treatment with Trimipramine.
\*\*Trimipramine Capsules contains sodium\*\*
This medicine contains less than 1 mmol sodium (23 mg) per capsule that is to say essentially 'sodium-free'.4.5 Interaction with other medicinal products and other forms of interaction
Trimipramine should not be given concurrently with, or within 2 weeks of cessation of, therapy with monoamine oxidase inhibitors. Trimipramine may decrease the antihypertensive effect of guanethidine, debrisoquine, betanidine and possibly clonidine. It would be advisable to review all antihypertensive therapy during treatment with tricyclic antidepressants.
Trimipramine should not be given with sympathomimetic agents such as adrenaline, ephedrine, isoprenaline, noradrenaline, phenylephrine and phenylpropanolamine.
Barbiturates may increase the rate of metabolism.
Trimipramine should be administered with care in patients receiving therapy for hyperthyroidism.
Co-administration with other serotonergic active substances (such as SSRIs, SNRIs, MAOIs, lithium, triptans, tramadol, linezolid, L-tryptophan, and St John's Wort –Hypericum perforatum-preparations) may lead to serotonin syndrome (see section 4.4). Close clinical monitoring is required when these substances are co-administered with trimipramine.
Trimipramine should be used cautiously when co-administered with:
• Buprenorphine/opioids as the risk of serotonin syndrome, a potentially life-threatening condition, is increased (see section 4.4).
Trimipramine should be used with caution in patients receiving drugs known to prolong QT interval (e.g. Class IA and III antiarrhythmics, macrolides, floroquinolones, some antifungals, some antipsychotics), induce hypokalemia (e.g. hypokalemic diuretics, stimulant laxatives, glucocorticoids, tetracosactides) or bradycardia (e.g. beta-blockers, diltiazem, verapamil, clonidine, digitalis) (see section 4.4).4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
Trimipramine should not be used during pregnancy especially during the first and last trimesters of pregnancy unless there are compelling reasons.
There is no evidence from animal studies that it is free from hazard.
\*\*Breast-feeding\*\*
Trimipramine is contraindicated during breast-feeding (see section 4.3).
\*\*Fertility\*\*
No data on the effects of trimipramine on human fertility are available.4.7 Effects on ability to drive and use machines
Trimipramine may initially impair alertness. Patients should be warned of the possible hazard when driving or operating machinery.4.8 Undesirable effects
Cases of suicidal ideation and suicidal behaviours have been reported during trimipramine therapy or early after treatment discontinuation (see section 4.4).
Cardiac arrhythmias and severe hypotension are likely to occur with high dosage or in deliberate overdosage. They may also occur in patients with pre-existing heart disease taking normal dosage. Other cardiac disorders include QT interval prolongation, torsade de pointes (see section 4.4)
The following adverse effects, although not necessarily all reported with trimipramine, have occurred with other tricyclic antidepressants.
Atropine-like side effects including dry mouth, disturbance of accommodation, tachycardia, constipation and hesitancy of micturation are common early in treatment but usually lessen.
Other common adverse effects include drowsiness, sweating, postural hypotension, tremor and skin rashes. Interference with sexual function may occur.
Serious adverse effects are rare; the following have been reported: depression of bone marrow, including agranulocytosis, cholestatic jaundice, hypomania, convulsions and peripheral neuropathy. Psychotic manifestations including mania and paranoid delusions, may be exacerbated during treatment with tricyclic antidepressants.
Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving SSRIs and TCAs. The mechanism leading to this risk is unknown.
Hyperglycaemia. Epidemiologic studies have identified an increased risk of diabetes mellitus in depressed patients receiving tricyclic antidepressants (see section 4.4).
Withdrawal symptoms may occur on abrupt cessation of therapy and include insomnia, irritability and excessive perspiration.
Adverse effects such as withdrawal symptoms, respiratory depression and agitation have been reported in neonates whose mothers had taken trimipramine during the last trimester of pregnancy.
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.co.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
Acute overdosage may be accompanied by hypotensive collapse, convulsions, coma, QT interval prolongation, torsades de pointes. Overdose may result in a fatal outcome.
Provided coma is not present, gastric lavage should be carried out without delay even though some time may have passed since the drug was ingested.
Patients in a coma should have an endotracheal tube passed before gastric lavage is started. Absorption of trimipramine is slow but, as cardiac effects may appear soon after the drug is absorbed, a saline purge should be given. Electrocardiography monitoring is essential.
It is important to treat acidosis as soon as it appears with, for example, 20 ml per kg of M/6 sodium lactate injection by slow intravenous injection.
Intubation is necessary and the patient should be ventilated before convulsions develop. Convulsions should be treated with diazepam administered intravenously.
Ventricular tachycardia or fibrillation should be treated by electrical defibrillation. If supraventricular tachycardia develops, pyridostigmine bromide 1 mg (adults) intravenously or propranolol 1mg (adults) should be administered at intervals as required.
Treatment should be continued for at least three days even if the patient appears to have recovered.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Psychoanaleptics; Non-selective monoamine reuptake inhibitors, ATC code: N06AA06.
Trimipramine is a tricyclic antidepressant. It has marked sedative properties.5.2 Pharmacokinetic properties
Trimipramine undergoes high first-pass hepatic clearance, with a mean value for bioavailability of about 41% after oral administration.
The absolute volume of distribution is 31 litres/kg. The metabolic clearance is 16 ml/mm/kg.
Plasma protein binding of trimipramine is about 95%. The plasma elimination half-life is around 23 hours. Trimipramine is largely metabolised by demethylation prior to conjugation yielding a glucuronide.5.3 Preclinical safety data
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, toxicity to reproduction.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
\*\*Capsule content:\*\*
Microcrystalline cellulose (E460)
Colloidal anhydrous silica
Croscarmellose Sodium
Pre-gelatinised Starch
Magnesium Stearate
\*\*Capsule shell:\*\*
Titanium dioxide (E171)
Indigotine (E132)
Iron oxide yellow (E172)
Gelatin
\*\*Printing ink (TekPrint™ SW-9008 Black Ink):\*\*
Shellac
Iron oxide black (E172)
Potassium hydroxide6.2 Incompatibilities
Not applicable6.3 Shelf life
2 years6.4 Special precautions for storage
For Aluminium/Aluminium Blister pack: This medicinal product does not require any special temperature storage conditions\*.\*
Store in the original package in order to protect from moisture.6.5 Nature and contents of container
Cartons containing Aluminium/Aluminium blisters of 28 capsules6.6 Special precautions for disposal and other handling
No special requirements.
- Instruction Content
- ## Composition
Each capsule contains 69.75mg of Trimipramine Maleate, equivalent to 50mg Trimipramine.
Excipients with known effect:
Each capsule contains 1.40 mg of sodium.
For the full list of excipients, see Section 6.1.
## Pharmaceutical Form
Capsule
Hard gelatin capsules approximately 19.20 x 6.93 mm in size with white opaque body imprinted with “301” in black ink and green cap imprinted with Glenmark logo “G” in black ink, filled with white to pale yellow powder.
## Clinical Particulars
4.1 Therapeutic indications
Trimipramine has a potent antidepressant action similar to that of other tricyclic antidepressants. It also possesses pronounced sedative action. It is, therefore, indicated in the treatment of depressive illness, especially where sleep disturbance, anxiety or agitation are presenting symptoms. Sleep disturbance is controlled within 24 hours and true antidepressant action follows within 7 to 10 days.4.2 Posology and method of administration
\*\*Posology\*\*
\*Adults\*
For depression 50-75 mg/day initially increasing to 150-300 mg/day in divided doses or one dose at night. The maintenance dose is 75-150 mg/day.
\*Elderly\*
10-25 mg three times a day initially. The initial dose should be increased with caution under close supervision. Half the normal maintenance dose may be sufficient to produce a satisfactory clinical response.
\*\*\*Paediatric population\*\*\*
Not recommended.
\*\*Method of administration\*\*
Oral.4.3 Contraindications
• Recent myocardial infarction
• Any degree of heart block or other cardiac arrhythmias
• Mania
• Severe liver disease
• During breast feeding
• Hypersensitivity to trimipramine maleate or to any of the excipients4.4 Special warnings and precautions for use
\*\*\*\*Suicide/suicidal thoughts or clinical worsening\*\*\*\*
Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.
Other psychiatric conditions for which Trimipramine is prescribed can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders.
Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.
Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.
\*\*Hyperglycaemia/Diabetes:\*\*
Epidemiologic studies have identified an increased risk of diabetes mellitus in depressed patients receiving tricyclic antidepressants. Therefore, patients with an established diagnosis of diabetes mellitus or with risk factors for diabetes who are started on trimipramine, should get appropriate glycaemic monitoring (see section 4.8).
\*\*Serotonin Syndrome:\*\*
Concomitant administration of Trimipramine and buprenorphine/opioids may result in serotonin syndrome, a potentially life-threatening condition (see section 4.5).
If concomitant treatment with other serotonergic agents is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
Symptoms of serotonin syndrome may include mental-status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms.
If serotonin syndrome is suspected, a dose reduction or discontinuation of therapy should be considered depending on the severity of the symptoms.
\*\*QT interval prolongation:\*\*
Like other tricyclic antidepressants, trimipramine may dose-dependently prolong QT interval (see section 4.8).
Caution should be taken in patients with known risk factors for prolongation of QT interval such as:
• congenital long QT syndrome, bradycardia
• concomitant use of drugs that are known to prolong the QT interval, induce bradycardia or hypokalemia (see section 4.5)
• uncorrected electrolyte imbalance (e.g. hypokalemia, hypomagnesemia).
The elderly are particularly liable to experience adverse reactions, especially agitation, confusion and postural hypotension.
Avoid if possible in patients with narrow angle glaucoma, symptoms suggestive of prostatic hypertrophy and a history of epilepsy.
Patients posing a high suicidal risk require close initial supervision. Tricyclic antidepressants potentiate the central nervous depressant action of alcohol.
Anaesthetics given during tri/tetracyclic antidepressant therapy may increase the risk of arrhythmias and hypotension. If surgery is necessary, the anaesthetist should be informed that a patient is being so treated.
It may be advisable to monitor liver function in patients on long term treatment with Trimipramine.
\*\*Trimipramine Capsules contains sodium\*\*
This medicine contains less than 1 mmol sodium (23 mg) per capsule that is to say essentially 'sodium-free'.4.5 Interaction with other medicinal products and other forms of interaction
Trimipramine should not be given concurrently with, or within 2 weeks of cessation of, therapy with monoamine oxidase inhibitors. Trimipramine may decrease the antihypertensive effect of guanethidine, debrisoquine, betanidine and possibly clonidine. It would be advisable to review all antihypertensive therapy during treatment with tricyclic antidepressants.
Trimipramine should not be given with sympathomimetic agents such as adrenaline, ephedrine, isoprenaline, noradrenaline, phenylephrine and phenylpropanolamine.
Barbiturates may increase the rate of metabolism.
Trimipramine should be administered with care in patients receiving therapy for hyperthyroidism.
Co-administration with other serotonergic active substances (such as SSRIs, SNRIs, MAOIs, lithium, triptans, tramadol, linezolid, L-tryptophan, and St John's Wort –Hypericum perforatum-preparations) may lead to serotonin syndrome (see section 4.4). Close clinical monitoring is required when these substances are co-administered with trimipramine.
Trimipramine should be used cautiously when co-administered with:
• Buprenorphine/opioids as the risk of serotonin syndrome, a potentially life-threatening condition, is increased (see section 4.4).
Trimipramine should be used with caution in patients receiving drugs known to prolong QT interval (e.g. Class IA and III antiarrhythmics, macrolides, floroquinolones, some antifungals, some antipsychotics), induce hypokalemia (e.g. hypokalemic diuretics, stimulant laxatives, glucocorticoids, tetracosactides) or bradycardia (e.g. beta-blockers, diltiazem, verapamil, clonidine, digitalis) (see section 4.4).4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
Trimipramine should not be used during pregnancy especially during the first and last trimesters of pregnancy unless there are compelling reasons.
There is no evidence from animal studies that it is free from hazard.
\*\*Breast-feeding\*\*
Trimipramine is contraindicated during breast-feeding (see section 4.3).
\*\*Fertility\*\*
No data on the effects of trimipramine on human fertility are available.4.7 Effects on ability to drive and use machines
Trimipramine may initially impair alertness. Patients should be warned of the possible hazard when driving or operating machinery.4.8 Undesirable effects
Cases of suicidal ideation and suicidal behaviours have been reported during trimipramine therapy or early after treatment discontinuation (see section 4.4).
Cardiac arrhythmias and severe hypotension are likely to occur with high dosage or in deliberate overdosage. They may also occur in patients with pre-existing heart disease taking normal dosage. Other cardiac disorders include QT interval prolongation, torsade de pointes (see section 4.4)
The following adverse effects, although not necessarily all reported with trimipramine, have occurred with other tricyclic antidepressants.
Atropine-like side effects including dry mouth, disturbance of accommodation, tachycardia, constipation and hesitancy of micturation are common early in treatment but usually lessen.
Other common adverse effects include drowsiness, sweating, postural hypotension, tremor and skin rashes. Interference with sexual function may occur.
Serious adverse effects are rare; the following have been reported: depression of bone marrow, including agranulocytosis, cholestatic jaundice, hypomania, convulsions and peripheral neuropathy. Psychotic manifestations including mania and paranoid delusions, may be exacerbated during treatment with tricyclic antidepressants.
Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving SSRIs and TCAs. The mechanism leading to this risk is unknown.
Hyperglycaemia. Epidemiologic studies have identified an increased risk of diabetes mellitus in depressed patients receiving tricyclic antidepressants (see section 4.4).
Withdrawal symptoms may occur on abrupt cessation of therapy and include insomnia, irritability and excessive perspiration.
Adverse effects such as withdrawal symptoms, respiratory depression and agitation have been reported in neonates whose mothers had taken trimipramine during the last trimester of pregnancy.
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.co.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
Acute overdosage may be accompanied by hypotensive collapse, convulsions, coma, QT interval prolongation, torsades de pointes. Overdose may result in a fatal outcome.
Provided coma is not present, gastric lavage should be carried out without delay even though some time may have passed since the drug was ingested.
Patients in a coma should have an endotracheal tube passed before gastric lavage is started. Absorption of trimipramine is slow but, as cardiac effects may appear soon after the drug is absorbed, a saline purge should be given. Electrocardiography monitoring is essential.
It is important to treat acidosis as soon as it appears with, for example, 20 ml per kg of M/6 sodium lactate injection by slow intravenous injection.
Intubation is necessary and the patient should be ventilated before convulsions develop. Convulsions should be treated with diazepam administered intravenously.
Ventricular tachycardia or fibrillation should be treated by electrical defibrillation. If supraventricular tachycardia develops, pyridostigmine bromide 1 mg (adults) intravenously or propranolol 1mg (adults) should be administered at intervals as required.
Treatment should be continued for at least three days even if the patient appears to have recovered.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Psychoanaleptics; Non-selective monoamine reuptake inhibitors, ATC code: N06AA06.
Trimipramine is a tricyclic antidepressant. It has marked sedative properties.5.2 Pharmacokinetic properties
Trimipramine undergoes high first-pass hepatic clearance, with a mean value for bioavailability of about 41% after oral administration.
The absolute volume of distribution is 31 litres/kg. The metabolic clearance is 16 ml/mm/kg.
Plasma protein binding of trimipramine is about 95%. The plasma elimination half-life is around 23 hours. Trimipramine is largely metabolised by demethylation prior to conjugation yielding a glucuronide.5.3 Preclinical safety data
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, toxicity to reproduction.
## Pharmaceutical Particulars
6.1 List of excipients
\*\*Capsule content:\*\*
Microcrystalline cellulose (E460)
Colloidal anhydrous silica
Croscarmellose Sodium
Pre-gelatinised Starch
Magnesium Stearate
\*\*Capsule shell:\*\*
Titanium dioxide (E171)
Indigotine (E132)
Iron oxide yellow (E172)
Gelatin
\*\*Printing ink (TekPrint™ SW-9008 Black Ink):\*\*
Shellac
Iron oxide black (E172)
Potassium hydroxide6.2 Incompatibilities
Not applicable6.3 Shelf life
2 years6.4 Special precautions for storage
For Aluminium/Aluminium Blister pack: This medicinal product does not require any special temperature storage conditions\*.\*
Store in the original package in order to protect from moisture.6.5 Nature and contents of container
Cartons containing Aluminium/Aluminium blisters of 28 capsules6.6 Special precautions for disposal and other handling
No special requirements.
